Report cover image

Global Live Attenuated Measles Vaccine Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 204 Pages
SKU # APRC20359573

Description

Summary

According to APO Research, the global Live Attenuated Measles Vaccine market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Live Attenuated Measles Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Live Attenuated Measles Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Live Attenuated Measles Vaccine market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Live Attenuated Measles Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Live Attenuated Measles Vaccine market include GSK, Bavarian Nordic, CSL Limited, Emergent Biosolutions, Medimmune, Sanofi-Pasteur, Serum Institute of India, Beijing Institute of Biological Products Co., Ltd and Pfizer, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Live Attenuated Measles Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Live Attenuated Measles Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Live Attenuated Measles Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Live Attenuated Measles Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Live Attenuated Measles Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Live Attenuated Measles Vaccine sales, projected growth trends, production technology, application and end-user industry.

Live Attenuated Measles Vaccine Segment by Company

GSK
Bavarian Nordic
CSL Limited
Emergent Biosolutions
Medimmune
Sanofi-Pasteur
Serum Institute of India
Beijing Institute of Biological Products Co., Ltd
Pfizer
Lanzhou Institute of Biological Products Co., Ltd
Merck
Novartis
Johnson & Johnson
Shanghai Institute of Biological Products Co., Ltd
Wuhan Institute of Biological Products Co., Ltd
Changchun Qijian Biological Products Co., Ltd
Live Attenuated Measles Vaccine Segment by Type

Liquid
Powder
Live Attenuated Measles Vaccine Segment by Application

Hospital
Clinic
Live Attenuated Measles Vaccine Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Live Attenuated Measles Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Live Attenuated Measles Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Live Attenuated Measles Vaccine significant trends, drivers, influence factors in global and regions.
6. To analyze Live Attenuated Measles Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Live Attenuated Measles Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Live Attenuated Measles Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Live Attenuated Measles Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Live Attenuated Measles Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Live Attenuated Measles Vaccine industry.
Chapter 3: Detailed analysis of Live Attenuated Measles Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Live Attenuated Measles Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Live Attenuated Measles Vaccine in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Table of Contents

204 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Live Attenuated Measles Vaccine Sales Value (2020-2031)
1.2.2 Global Live Attenuated Measles Vaccine Sales Volume (2020-2031)
1.2.3 Global Live Attenuated Measles Vaccine Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Live Attenuated Measles Vaccine Market Dynamics
2.1 Live Attenuated Measles Vaccine Industry Trends
2.2 Live Attenuated Measles Vaccine Industry Drivers
2.3 Live Attenuated Measles Vaccine Industry Opportunities and Challenges
2.4 Live Attenuated Measles Vaccine Industry Restraints
3 Live Attenuated Measles Vaccine Market by Company
3.1 Global Live Attenuated Measles Vaccine Company Revenue Ranking in 2024
3.2 Global Live Attenuated Measles Vaccine Revenue by Company (2020-2025)
3.3 Global Live Attenuated Measles Vaccine Sales Volume by Company (2020-2025)
3.4 Global Live Attenuated Measles Vaccine Average Price by Company (2020-2025)
3.5 Global Live Attenuated Measles Vaccine Company Ranking (2023-2025)
3.6 Global Live Attenuated Measles Vaccine Company Manufacturing Base and Headquarters
3.7 Global Live Attenuated Measles Vaccine Company Product Type and Application
3.8 Global Live Attenuated Measles Vaccine Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Live Attenuated Measles Vaccine Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Live Attenuated Measles Vaccine Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Live Attenuated Measles Vaccine Market by Type
4.1 Live Attenuated Measles Vaccine Type Introduction
4.1.1 Liquid
4.1.2 Powder
4.2 Global Live Attenuated Measles Vaccine Sales Volume by Type
4.2.1 Global Live Attenuated Measles Vaccine Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Live Attenuated Measles Vaccine Sales Volume by Type (2020-2031)
4.2.3 Global Live Attenuated Measles Vaccine Sales Volume Share by Type (2020-2031)
4.3 Global Live Attenuated Measles Vaccine Sales Value by Type
4.3.1 Global Live Attenuated Measles Vaccine Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Live Attenuated Measles Vaccine Sales Value by Type (2020-2031)
4.3.3 Global Live Attenuated Measles Vaccine Sales Value Share by Type (2020-2031)
5 Live Attenuated Measles Vaccine Market by Application
5.1 Live Attenuated Measles Vaccine Application Introduction
5.1.1 Hospital
5.1.2 Clinic
5.2 Global Live Attenuated Measles Vaccine Sales Volume by Application
5.2.1 Global Live Attenuated Measles Vaccine Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Live Attenuated Measles Vaccine Sales Volume by Application (2020-2031)
5.2.3 Global Live Attenuated Measles Vaccine Sales Volume Share by Application (2020-2031)
5.3 Global Live Attenuated Measles Vaccine Sales Value by Application
5.3.1 Global Live Attenuated Measles Vaccine Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Live Attenuated Measles Vaccine Sales Value by Application (2020-2031)
5.3.3 Global Live Attenuated Measles Vaccine Sales Value Share by Application (2020-2031)
6 Live Attenuated Measles Vaccine Regional Sales and Value Analysis
6.1 Global Live Attenuated Measles Vaccine Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Live Attenuated Measles Vaccine Sales by Region (2020-2031)
6.2.1 Global Live Attenuated Measles Vaccine Sales by Region: 2020-2025
6.2.2 Global Live Attenuated Measles Vaccine Sales by Region (2026-2031)
6.3 Global Live Attenuated Measles Vaccine Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Live Attenuated Measles Vaccine Sales Value by Region (2020-2031)
6.4.1 Global Live Attenuated Measles Vaccine Sales Value by Region: 2020-2025
6.4.2 Global Live Attenuated Measles Vaccine Sales Value by Region (2026-2031)
6.5 Global Live Attenuated Measles Vaccine Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Live Attenuated Measles Vaccine Sales Value (2020-2031)
6.6.2 North America Live Attenuated Measles Vaccine Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Live Attenuated Measles Vaccine Sales Value (2020-2031)
6.7.2 Europe Live Attenuated Measles Vaccine Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Live Attenuated Measles Vaccine Sales Value (2020-2031)
6.8.2 Asia-Pacific Live Attenuated Measles Vaccine Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Live Attenuated Measles Vaccine Sales Value (2020-2031)
6.9.2 South America Live Attenuated Measles Vaccine Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Live Attenuated Measles Vaccine Sales Value (2020-2031)
6.10.2 Middle East & Africa Live Attenuated Measles Vaccine Sales Value Share by Country, 2024 VS 2031
7 Live Attenuated Measles Vaccine Country-level Sales and Value Analysis
7.1 Global Live Attenuated Measles Vaccine Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Live Attenuated Measles Vaccine Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Live Attenuated Measles Vaccine Sales by Country (2020-2031)
7.3.1 Global Live Attenuated Measles Vaccine Sales by Country (2020-2025)
7.3.2 Global Live Attenuated Measles Vaccine Sales by Country (2026-2031)
7.4 Global Live Attenuated Measles Vaccine Sales Value by Country (2020-2031)
7.4.1 Global Live Attenuated Measles Vaccine Sales Value by Country (2020-2025)
7.4.2 Global Live Attenuated Measles Vaccine Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Live Attenuated Measles Vaccine Sales Value Growth Rate (2020-2031)
7.5.2 USA Live Attenuated Measles Vaccine Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Live Attenuated Measles Vaccine Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Live Attenuated Measles Vaccine Sales Value Growth Rate (2020-2031)
7.6.2 Canada Live Attenuated Measles Vaccine Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Live Attenuated Measles Vaccine Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Live Attenuated Measles Vaccine Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Live Attenuated Measles Vaccine Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Live Attenuated Measles Vaccine Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Live Attenuated Measles Vaccine Sales Value Growth Rate (2020-2031)
7.8.2 Germany Live Attenuated Measles Vaccine Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Live Attenuated Measles Vaccine Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Live Attenuated Measles Vaccine Sales Value Growth Rate (2020-2031)
7.9.2 France Live Attenuated Measles Vaccine Sales Value Share by Type, 2024 VS 2031
7.9.3 France Live Attenuated Measles Vaccine Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Live Attenuated Measles Vaccine Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Live Attenuated Measles Vaccine Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Live Attenuated Measles Vaccine Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Live Attenuated Measles Vaccine Sales Value Growth Rate (2020-2031)
7.11.2 Italy Live Attenuated Measles Vaccine Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Live Attenuated Measles Vaccine Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Live Attenuated Measles Vaccine Sales Value Growth Rate (2020-2031)
7.12.2 Spain Live Attenuated Measles Vaccine Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Live Attenuated Measles Vaccine Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Live Attenuated Measles Vaccine Sales Value Growth Rate (2020-2031)
7.13.2 Russia Live Attenuated Measles Vaccine Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Live Attenuated Measles Vaccine Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Live Attenuated Measles Vaccine Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Live Attenuated Measles Vaccine Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Live Attenuated Measles Vaccine Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Live Attenuated Measles Vaccine Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Live Attenuated Measles Vaccine Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Live Attenuated Measles Vaccine Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Live Attenuated Measles Vaccine Sales Value Growth Rate (2020-2031)
7.16.2 China Live Attenuated Measles Vaccine Sales Value Share by Type, 2024 VS 2031
7.16.3 China Live Attenuated Measles Vaccine Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Live Attenuated Measles Vaccine Sales Value Growth Rate (2020-2031)
7.17.2 Japan Live Attenuated Measles Vaccine Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Live Attenuated Measles Vaccine Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Live Attenuated Measles Vaccine Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Live Attenuated Measles Vaccine Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Live Attenuated Measles Vaccine Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Live Attenuated Measles Vaccine Sales Value Growth Rate (2020-2031)
7.19.2 India Live Attenuated Measles Vaccine Sales Value Share by Type, 2024 VS 2031
7.19.3 India Live Attenuated Measles Vaccine Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Live Attenuated Measles Vaccine Sales Value Growth Rate (2020-2031)
7.20.2 Australia Live Attenuated Measles Vaccine Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Live Attenuated Measles Vaccine Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Live Attenuated Measles Vaccine Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Live Attenuated Measles Vaccine Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Live Attenuated Measles Vaccine Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Live Attenuated Measles Vaccine Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Live Attenuated Measles Vaccine Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Live Attenuated Measles Vaccine Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Live Attenuated Measles Vaccine Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Live Attenuated Measles Vaccine Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Live Attenuated Measles Vaccine Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Live Attenuated Measles Vaccine Sales Value Growth Rate (2020-2031)
7.24.2 Chile Live Attenuated Measles Vaccine Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Live Attenuated Measles Vaccine Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Live Attenuated Measles Vaccine Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Live Attenuated Measles Vaccine Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Live Attenuated Measles Vaccine Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Live Attenuated Measles Vaccine Sales Value Growth Rate (2020-2031)
7.26.2 Peru Live Attenuated Measles Vaccine Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Live Attenuated Measles Vaccine Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Live Attenuated Measles Vaccine Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Live Attenuated Measles Vaccine Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Live Attenuated Measles Vaccine Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Live Attenuated Measles Vaccine Sales Value Growth Rate (2020-2031)
7.28.2 Israel Live Attenuated Measles Vaccine Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Live Attenuated Measles Vaccine Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Live Attenuated Measles Vaccine Sales Value Growth Rate (2020-2031)
7.29.2 UAE Live Attenuated Measles Vaccine Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Live Attenuated Measles Vaccine Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Live Attenuated Measles Vaccine Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Live Attenuated Measles Vaccine Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Live Attenuated Measles Vaccine Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Live Attenuated Measles Vaccine Sales Value Growth Rate (2020-2031)
7.31.2 Iran Live Attenuated Measles Vaccine Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Live Attenuated Measles Vaccine Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Live Attenuated Measles Vaccine Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Live Attenuated Measles Vaccine Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Live Attenuated Measles Vaccine Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 GSK
8.1.1 GSK Comapny Information
8.1.2 GSK Business Overview
8.1.3 GSK Live Attenuated Measles Vaccine Sales, Value and Gross Margin (2020-2025)
8.1.4 GSK Live Attenuated Measles Vaccine Product Portfolio
8.1.5 GSK Recent Developments
8.2 Bavarian Nordic
8.2.1 Bavarian Nordic Comapny Information
8.2.2 Bavarian Nordic Business Overview
8.2.3 Bavarian Nordic Live Attenuated Measles Vaccine Sales, Value and Gross Margin (2020-2025)
8.2.4 Bavarian Nordic Live Attenuated Measles Vaccine Product Portfolio
8.2.5 Bavarian Nordic Recent Developments
8.3 CSL Limited
8.3.1 CSL Limited Comapny Information
8.3.2 CSL Limited Business Overview
8.3.3 CSL Limited Live Attenuated Measles Vaccine Sales, Value and Gross Margin (2020-2025)
8.3.4 CSL Limited Live Attenuated Measles Vaccine Product Portfolio
8.3.5 CSL Limited Recent Developments
8.4 Emergent Biosolutions
8.4.1 Emergent Biosolutions Comapny Information
8.4.2 Emergent Biosolutions Business Overview
8.4.3 Emergent Biosolutions Live Attenuated Measles Vaccine Sales, Value and Gross Margin (2020-2025)
8.4.4 Emergent Biosolutions Live Attenuated Measles Vaccine Product Portfolio
8.4.5 Emergent Biosolutions Recent Developments
8.5 Medimmune
8.5.1 Medimmune Comapny Information
8.5.2 Medimmune Business Overview
8.5.3 Medimmune Live Attenuated Measles Vaccine Sales, Value and Gross Margin (2020-2025)
8.5.4 Medimmune Live Attenuated Measles Vaccine Product Portfolio
8.5.5 Medimmune Recent Developments
8.6 Sanofi-Pasteur
8.6.1 Sanofi-Pasteur Comapny Information
8.6.2 Sanofi-Pasteur Business Overview
8.6.3 Sanofi-Pasteur Live Attenuated Measles Vaccine Sales, Value and Gross Margin (2020-2025)
8.6.4 Sanofi-Pasteur Live Attenuated Measles Vaccine Product Portfolio
8.6.5 Sanofi-Pasteur Recent Developments
8.7 Serum Institute of India
8.7.1 Serum Institute of India Comapny Information
8.7.2 Serum Institute of India Business Overview
8.7.3 Serum Institute of India Live Attenuated Measles Vaccine Sales, Value and Gross Margin (2020-2025)
8.7.4 Serum Institute of India Live Attenuated Measles Vaccine Product Portfolio
8.7.5 Serum Institute of India Recent Developments
8.8 Beijing Institute of Biological Products Co., Ltd
8.8.1 Beijing Institute of Biological Products Co., Ltd Comapny Information
8.8.2 Beijing Institute of Biological Products Co., Ltd Business Overview
8.8.3 Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Value and Gross Margin (2020-2025)
8.8.4 Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
8.8.5 Beijing Institute of Biological Products Co., Ltd Recent Developments
8.9 Pfizer
8.9.1 Pfizer Comapny Information
8.9.2 Pfizer Business Overview
8.9.3 Pfizer Live Attenuated Measles Vaccine Sales, Value and Gross Margin (2020-2025)
8.9.4 Pfizer Live Attenuated Measles Vaccine Product Portfolio
8.9.5 Pfizer Recent Developments
8.10 Lanzhou Institute of Biological Products Co., Ltd
8.10.1 Lanzhou Institute of Biological Products Co., Ltd Comapny Information
8.10.2 Lanzhou Institute of Biological Products Co., Ltd Business Overview
8.10.3 Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Value and Gross Margin (2020-2025)
8.10.4 Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
8.10.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments
8.11 Merck
8.11.1 Merck Comapny Information
8.11.2 Merck Business Overview
8.11.3 Merck Live Attenuated Measles Vaccine Sales, Value and Gross Margin (2020-2025)
8.11.4 Merck Live Attenuated Measles Vaccine Product Portfolio
8.11.5 Merck Recent Developments
8.12 Novartis
8.12.1 Novartis Comapny Information
8.12.2 Novartis Business Overview
8.12.3 Novartis Live Attenuated Measles Vaccine Sales, Value and Gross Margin (2020-2025)
8.12.4 Novartis Live Attenuated Measles Vaccine Product Portfolio
8.12.5 Novartis Recent Developments
8.13 Johnson & Johnson
8.13.1 Johnson & Johnson Comapny Information
8.13.2 Johnson & Johnson Business Overview
8.13.3 Johnson & Johnson Live Attenuated Measles Vaccine Sales, Value and Gross Margin (2020-2025)
8.13.4 Johnson & Johnson Live Attenuated Measles Vaccine Product Portfolio
8.13.5 Johnson & Johnson Recent Developments
8.14 Shanghai Institute of Biological Products Co., Ltd
8.14.1 Shanghai Institute of Biological Products Co., Ltd Comapny Information
8.14.2 Shanghai Institute of Biological Products Co., Ltd Business Overview
8.14.3 Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Value and Gross Margin (2020-2025)
8.14.4 Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
8.14.5 Shanghai Institute of Biological Products Co., Ltd Recent Developments
8.15 Wuhan Institute of Biological Products Co., Ltd
8.15.1 Wuhan Institute of Biological Products Co., Ltd Comapny Information
8.15.2 Wuhan Institute of Biological Products Co., Ltd Business Overview
8.15.3 Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Value and Gross Margin (2020-2025)
8.15.4 Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
8.15.5 Wuhan Institute of Biological Products Co., Ltd Recent Developments
8.16 Changchun Qijian Biological Products Co., Ltd
8.16.1 Changchun Qijian Biological Products Co., Ltd Comapny Information
8.16.2 Changchun Qijian Biological Products Co., Ltd Business Overview
8.16.3 Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Value and Gross Margin (2020-2025)
8.16.4 Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
8.16.5 Changchun Qijian Biological Products Co., Ltd Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Live Attenuated Measles Vaccine Value Chain Analysis
9.1.1 Live Attenuated Measles Vaccine Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Live Attenuated Measles Vaccine Sales Mode & Process
9.2 Live Attenuated Measles Vaccine Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Live Attenuated Measles Vaccine Distributors
9.2.3 Live Attenuated Measles Vaccine Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.